Webinar: Companion Diagnostics In Oncology
Executive Summary
Precision medicine and companion diagnostics are now core elements underlying the development of new oncology therapies, and they will certainly be major themes at the American Society of Clinical Oncology annual meeting set to kick off this week in Chicago. In advance of the ASCO confab, check out this webinar, coproduced by Medtech Insight and Pink Sheet, addressing technology and regulatory drivers for companion diagnostics and key clinical development considerations for pharma companies.
You may also be interested in...
Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.